New hope for stubborn lung disease as trial tests powerful drug combo
NCT ID NCT02990286
Summary
This study tested whether adding rituximab to standard mycophenolate treatment helps patients with progressive lung scarring who didn't improve on their first treatment. 122 adults received either the drug combination or mycophenolate alone for 6 months. Researchers measured whether the combination better preserved lung function and quality of life compared to standard treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG DISEASE, INTERSTITIAL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AP-HM Hôpital NORD
Marseille, 13015, France
-
CHRU Tours
Tours, 37044, France
-
Chu Besancon
Besançon, 25030, France
-
Chu Dijon
Dijon, 21079, France
-
Chu Rennes
Rennes, 35033, France
Conditions
Explore the condition pages connected to this study.